Why carry out this study?

Biosimilars of anti-vascular endothelial growth factor (anti-VEGF) drugs are an appealing therapeutic alternative to the parent biologic since they have the potential to reduce the cumulative cost of treatment in various chorioretinal disorders. Although the Indian drug regulator-approved ranibizumab biosimilar Razumab (Intas Pharmaceuticals, Ahmedabad, India) has demonstrated good efficacy and safety based on phase III studies, the limited number of patients treated in a controlled environment may not truly reflect the delivery settings and the population diversities in real-world scenarios.

What was learned from the study?

In a real-world setting, biosimilar ranibizumab is similar to innovator ranibizumab in improving vision and reducing central macular thickness (CMT) in eyes with diabetic macular edema (DME) in the short term. Intravitreal biosimilar ranibizumab has an acceptable ocular and systemic safety profile in patients with diabetic macular edema.